Pre-made Flotetuzumab benchmark antibody ( Bispecific scFv with Crossover, anti-IL3RA;CD3E therapeutic antibody, Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Flotetuzumab biosimilar, Bispecific scFv with Crossover, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Flotetuzumab (INN; development code MGD006) is a bispecific antibody designed for the treatment of acute myeloid leukemia.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-218-1mg	1mg	Inquiry
GMP-Bios-ab-218-10mg	10mg	Inquiry
GMP-Bios-ab-218-100mg	100mg	Inquiry
GMP-Bios-ab-218-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Flotetuzumab biosimilar, Bispecific scFv with Crossover, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibody
INN Name	Flotetuzumab
Target	IL3RA;CD3E
Format	Bispecific scFv with Crossover
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	na
VD LC	Kappa;Lambda
Highest_Clin_Trial (Jan '20)	Phase-I/II
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2017
Year Recommended	2018
Companies	MacroGenics;Servier
Conditions Approved	na
Conditions Active	Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma
Conditions Discontinued	na
Development Tech	Dual-Affinity Re-Targeting Technology